{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:53:18Z","timestamp":1792270398490,"version":"4.4.0"},"reference-count":98,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.semnephrol.2023.151341","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T07:05:28Z","timestamp":1683875128000},"page":"151341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Cisplatin Nephrotoxicity: Novel Insights Into Mechanisms and Preventative Strategies"],"prefix":"10.1016","volume":"42","author":[{"given":"Shveta S.","family":"Motwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharneet K.","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijat","family":"Kitchlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.semnephrol.2023.151341_bib0001","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.semnephrol.2023.151341_bib0002","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151341_bib0003","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11864-020-00767-3","article-title":"New treatment options for advanced biliary tract cancer","volume":"21","author":"Mizrahi","year":"2020","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151341_bib0004","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","article-title":"Defining cisplatin eligibility in patients with muscle-invasive bladder cancer","volume":"18","author":"Jiang","year":"2021","journal-title":"Nat Rev Urol"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151341_bib0005","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1038\/sj.ki.5002786","article-title":"Cisplatin nephrotoxicity: mechanisms and renoprotective strategies","volume":"73","author":"Pabla","year":"2008","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151341_bib0006","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/0024-3205(83)90299-0","article-title":"Minireview. The nephrotoxicity of cisplatin","volume":"32","author":"Goldstein","year":"1983","journal-title":"Life Sci"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151341_bib0007","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.0.CO;2-9","article-title":"Platinum organ toxicity and possible prevention in patients with testicular cancer","volume":"83","author":"Hartmann","year":"1999","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151341_bib0008","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1200\/JCO.2017.75.7161","article-title":"Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin","volume":"36","author":"Motwani","year":"2018","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151341_bib0009","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40620-017-0392-z","article-title":"Cisplatin nephrotoxicity: a review of the literature","volume":"31","author":"Manohar","year":"2018","journal-title":"J Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151341_bib0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0002-9343(78)90825-2","article-title":"Platinum nephrotoxicity","volume":"65","author":"Madias","year":"1978","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151341_bib0011","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0305-7372(98)90061-5","article-title":"Cumulative toxicities from cisplatin therapy and current cytoprotective measures","volume":"24","author":"Cvitkovic","year":"1998","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151341_bib0012","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nbt0510-436","article-title":"Next-generation biomarkers for detecting kidney toxicity","volume":"28","author":"Bonventre","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151341_bib0013","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/nbt.1623","article-title":"Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies","volume":"28","author":"Vaidya","year":"2010","journal-title":"Nat Biotechnol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151341_bib0014","doi-asserted-by":"crossref","first-page":"F552","DOI":"10.1152\/ajprenal.00285.2002","article-title":"Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury","volume":"286","author":"Ichimura","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151341_bib0015","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00280-015-2880-y","article-title":"Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients","volume":"76","author":"Shinke","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151341_bib0016","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2310\/JIM.0b013e31828233a8","volume":"61","author":"Sinha","year":"2013","journal-title":"J Investig Med"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151341_bib0017","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2215\/CJN.08070715","article-title":"Long-term renal outcomes after cisplatin treatment","volume":"11","author":"Latcha","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151341_bib0018","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/sj.bjc.6600884","article-title":"Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients","volume":"88","author":"de Jongh","year":"2003","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151341_bib0019","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s002800050661","article-title":"Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods","volume":"40","author":"Stewart","year":"1997","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151341_bib0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142225","article-title":"Understanding the risk factors and long-term consequences of cisplatin-associated acute kidney injury: an observational cohort study","volume":"10","author":"Bhat","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151341_bib0021","doi-asserted-by":"crossref","first-page":"F369","DOI":"10.1152\/ajprenal.00127.2014","article-title":"Magnesium protects against cisplatin-induced acute kidney injury by regulating platinum accumulation","volume":"307","author":"Solanki","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151341_bib0022","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/2050-6511-15-70","article-title":"Magnesium supplementation and high volume hydration reduce the renal toxicity caused by cisplatin-based chemotherapy in patients with lung cancer: a toxicity study","volume":"15","author":"Oka","year":"2014","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151341_bib0023","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/jjco\/hyu004","article-title":"Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: a retrospective study","volume":"44","author":"Yoshida","year":"2014","journal-title":"Jpn J Clin Oncol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151341_bib0024","first-page":"2199","article-title":"Nephroprotective effects of hydration with magnesium in patients with cervical cancer receiving cisplatin","volume":"35","author":"Yamamoto","year":"2015","journal-title":"Anticancer Res"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151341_bib0025","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/clpt.2009.139","article-title":"Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity","volume":"86","author":"Filipski","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151341_bib0026","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.2353\/ajpath.2010.090610","article-title":"Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions","volume":"176","author":"Ciarimboli","year":"2010","journal-title":"Am J Pathol"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151341_bib0027","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3390\/jpm11111233","article-title":"Association between genetic variants and cisplatin-induced nephrotoxicity: a genome-wide approach and validation study","volume":"11","author":"Zazuli","year":"2021","journal-title":"J Pers Med"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151341_bib0028","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.3390\/toxins2112490","article-title":"Mechanisms of cisplatin nephrotoxicity","volume":"2","author":"Miller","year":"2010","journal-title":"Toxins (Basel)"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151341_bib0029","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/ndt\/12.12.2478","article-title":"Insights into potential cellular mechanisms of cisplatin nephrotoxicity and their clinical application","volume":"12","author":"Kuhlmann","year":"1997","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151341_bib0030","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0002-9440(10)61234-5","article-title":"Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2","volume":"167","author":"Ciarimboli","year":"2005","journal-title":"Am J Pathol"},{"issue":"22","key":"10.1016\/j.semnephrol.2023.151341_bib0031","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.1073\/pnas.162491399","article-title":"From the cover: uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals","volume":"99","author":"Ishida","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151341_bib0032","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3390\/cancers13071572","article-title":"Mechanisms of cisplatin-induced acute kidney injury: pathological mechanisms, pharmacological interventions, and genetic mitigations","volume":"13","author":"McSweeney","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.semnephrol.2023.151341_bib0033","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/bs.acr.2021.03.008","article-title":"Cisplatin chemotherapy and renal function","volume":"152","author":"Zhang","year":"2021","journal-title":"Adv Cancer Res"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151341_bib0034","article-title":"Membrane transporters as mediators of cisplatin side-effects","volume":"34","author":"Ciarimboli","year":"2014","journal-title":"Anticancer Res"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151341_bib0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.5306\/wjco.v7.i1.106","article-title":"Role of copper transporters in platinum resistance","volume":"7","author":"Kilari","year":"2016","journal-title":"World J Clin Oncol"},{"issue":"43","key":"10.1016\/j.semnephrol.2023.151341_bib0036","doi-asserted-by":"crossref","first-page":"40253","DOI":"10.1074\/jbc.M208002200","article-title":"Characterization of mouse embryonic cells deficient in the ctr1 high affinity copper transporter. Identification of a Ctr1-independent copper transport system","volume":"277","author":"Lee","year":"2002","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151341_bib0037","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1634\/theoncologist.2016-0319","article-title":"A systematic review of strategies to prevent cisplatin-induced nephrotoxicity","volume":"22","author":"Crona","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.semnephrol.2023.151341_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.804685","article-title":"Protective effect of mannitol on cisplatin-induced nephrotoxicity: a systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol."},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151341_bib0039","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1248\/bpb.33.1867","article-title":"Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity","volume":"33","author":"Katsuda","year":"2010","journal-title":"Biol Pharm Bull"},{"issue":"11","key":"10.1016\/j.semnephrol.2023.151341_bib0040","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11095-018-2486-2","article-title":"Selective inhibition on organic cation transporters by carvedilol protects mice from cisplatin-induced nephrotoxicity","volume":"35","author":"Guo","year":"2018","journal-title":"Pharm Res"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151341_bib0041","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12032-021-01558-y","article-title":"Possible protective effect of pantoprazole against cisplatin-induced nephrotoxicity in head and neck cancer patients: a randomized controlled trial","volume":"38","author":"Ghonaim","year":"2021","journal-title":"Med Oncol"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151341_bib0042","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1634\/theoncologist.2018-0037","article-title":"Pantoprazole, an inhibitor of the organic cation transporter 2, does not ameliorate cisplatin-related ototoxicity or nephrotoxicity in children and adolescents with newly diagnosed osteosarcoma treated with methotrexate, doxorubicin, and cisplatin","volume":"23","author":"Fox","year":"2018","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151341_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100351","article-title":"Preloading magnesium attenuates cisplatin-associated nephrotoxicity: pilot randomized controlled trial (PRAGMATIC study)","volume":"7","author":"Suppadungsuk","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.semnephrol.2023.151341_bib0044","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2017.05.034","article-title":"Magnesium attenuates cisplatin-induced nephrotoxicity by regulating the expression of renal transporters","volume":"811","author":"Saito","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"14","key":"10.1016\/j.semnephrol.2023.151341_bib0045","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1007\/s40265-019-01182-1","article-title":"Prevention of cisplatin-induced acute kidney injury: a systematic review and meta-analysis","volume":"79","author":"Hamroun","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.semnephrol.2023.151341_bib0046","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.2147\/OTT.S86743","article-title":"Significance of downregulation of renal organic cation transporter (SLC47A1) in cisplatin-induced proximal tubular injury","volume":"8","author":"Mizuno","year":"2015","journal-title":"Onco Targets Ther"},{"issue":"9","key":"10.1016\/j.semnephrol.2023.151341_bib0047","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.3390\/antiox10091329","article-title":"Mitochondrial superoxide dismutase in cisplatin-induced kidney injury","volume":"10","author":"Mapuskar","year":"2021","journal-title":"Antioxidants"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151341_bib0048","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1046\/j.1523-1755.2003.00908.x","article-title":"Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis","volume":"63","author":"Liu","year":"2003","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151341_bib0049","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3892\/mmr.2012.1033","article-title":"Evaluation of the effect of glutathione on cisplatin antitumor activity and kidney injury at different administration times","volume":"6","author":"Xu","year":"2012","journal-title":"Mol Med Rep"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151341_bib0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.29245\/2767-5149\/2021\/1.1109","article-title":"Amifostine is a nephro-protectant in patients receiving treatment with cisplatin- myth, mystery or matter-of-fact?","volume":"3","author":"Ha","year":"2021","journal-title":"J Nephrol Sci"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151341_bib0051","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.1996.14.7.2101","article-title":"Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer","volume":"14","author":"Kemp","year":"1996","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151341_bib0052","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2002.04.178","article-title":"2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology","volume":"20","author":"Schuchter","year":"2002","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151341_bib0053","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/s41401-021-00620-9","article-title":"Natural products: potential treatments for cisplatin-induced nephrotoxicity","volume":"42","author":"Yan FC","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.semnephrol.2023.151341_bib0054","unstructured":"Devine A, Marignol L. Potential of amifostine for chemoradiotherapy and radiotherapy-associated toxicity reduction in advanced NSCLC: a meta-analysis - PubMed. Accessed February 12, 2023. https:\/\/pubmed.ncbi.nlm.nih.gov\/26722022"},{"key":"10.1016\/j.semnephrol.2023.151341_bib0055","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.redox.2018.09.020","article-title":"Persistent increase in mitochondrial superoxide mediates cisplatin-induced chronic kidney disease","volume":"20","author":"Mapuskar","year":"2019","journal-title":"Redox Biol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151341_bib0056","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.freeradbiomed.2011.11.001","article-title":"Mitochondrial-targeted antioxidants represent a promising approach for prevention of cisplatin-induced nephropathy","volume":"52","author":"Mukhopadhyay","year":"2012","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151341_bib0057","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00280-017-3358-x","article-title":"Involvement of cytochrome P450 in cisplatin treatment: implications for toxicity","volume":"80","author":"Quintanilha","year":"2017","journal-title":"Cancer Chemother Pharmacol."},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151341_bib0058","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.ackd.2021.08.001","article-title":"Conventional chemotherapy nephrotoxicity","volume":"28","author":"Gupta","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.semnephrol.2023.151341_bib0059","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1752-0509-6-122","article-title":"Computational modeling of apoptotic signaling pathways induced by cisplatin","volume":"6","author":"Hong","year":"2012","journal-title":"BMC Syst Biol"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151341_bib0060","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1152\/ajprenal.00230.2007","article-title":"Activation and involvement of p53 in cisplatin-induced nephrotoxicity","volume":"293","author":"Wei","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151341_bib0061","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1152\/ajprenal.00262.2004","article-title":"Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity","volume":"287","author":"Jiang","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151341_bib0062","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/sj.ki.5002256","article-title":"The pathological role of Bax in cisplatin nephrotoxicity","volume":"72","author":"Wei","year":"2007","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151341_bib0063","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1681\/ASN.2004090768","article-title":"Endoplasmic reticulum stress\u2013associated caspase 12 mediates cisplatin-induced LLC-PK1 cell apoptosis","volume":"16","author":"Liu","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"35","key":"10.1016\/j.semnephrol.2023.151341_bib0064","doi-asserted-by":"crossref","first-page":"31230","DOI":"10.1074\/jbc.M503305200","article-title":"p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury","volume":"280","author":"Seth","year":"2005","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151341_bib0065","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1046\/j.1523-1755.2003.00709.x","article-title":"Direct involvement of the receptor-mediated apoptotic pathways in cisplatin-induced renal tubular cell death","volume":"63","author":"Tsuruya","year":"2003","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151341_bib0066","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1523-1755.2004.00413.x","article-title":"Salicylate reduces cisplatin nephrotoxicity by inhibition of tumor necrosis factor-\u03b1","volume":"65","author":"Ramesh","year":"2004","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151341_bib0067","doi-asserted-by":"crossref","first-page":"457","DOI":"10.31557\/APJCP.2021.22.2.457","article-title":"Effect of intravenous glutamine on caspase-12 expression in the apoptosis of the glomerular epithelial cells of male rats exposed to cisplatin","volume":"22","author":"Fakhrinnisa","year":"2021","journal-title":"Asian Pac J Cancer Prev"},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151341_bib0068","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1681\/ASN.2020101455","article-title":"Potential therapeutic targets for cisplatin-induced kidney injury: lessons from other models of AKI and fibrosis","volume":"32","author":"Sears","year":"2021","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.semnephrol.2023.151341_bib0069","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4212\/cjhp.v70i2.1641","article-title":"Risk factors for nephrotoxicity associated with cisplatin","volume":"70","author":"Almanric","year":"2017","journal-title":"Can J Hosp Pharm"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151341_bib0070","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.3639","article-title":"Epidemiologic characteristics of acute kidney injury during cisplatin infusions in children treated for cancer","volume":"3","author":"McMahon","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.semnephrol.2023.151341_bib0071","unstructured":"KDIGO clinical practice guideline for acute kidney injury. doi:10.1038\/kisup.2012. https:\/\/kdigo.org\/guidelines\/acute-kidney-injury\/. Accessed March 10, 2023."},{"key":"10.1016\/j.semnephrol.2023.151341_bib0072","unstructured":"IG Glezerman and EA Jaimes, Chapter 11. Chemotherapy and kidney Injury, 2016.https:\/\/www.semanticscholar.org\/paper\/Chapter-11-.-Chemotherapy-and-Kidney-Injury-Glezerman-Jaimes\/60f75c290be56f6454d7e8a22263f92f15f8d7a5. Accessed on March 10, 2023."},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151341_bib0073","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S0270-9295(03)00089-5","article-title":"Cisplatin nephrotoxicity","volume":"23","author":"Arany","year":"2003","journal-title":"Semin Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151341_bib0074","first-page":"1310","article-title":"Clinical and pharmacological studies with cis-diamminedichloroplatinum (II)","volume":"33","author":"Deconti","year":"1973","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151341_bib0075","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2215\/CJN.11290821","article-title":"Drug-induced acute kidney injury","volume":"17","author":"Perazella","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151341_bib0076","doi-asserted-by":"crossref","DOI":"10.1590\/1414-431x2021e11353","article-title":"Renal fibrosis due to multiple cisplatin treatment is exacerbated by kinin B1 receptor antagonism","volume":"54","author":"Budu","year":"2021","journal-title":"Braz J Med Biol Res"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151341_bib0077","doi-asserted-by":"crossref","first-page":"439","DOI":"10.21873\/invivo.11080","article-title":"Thrombotic microangiopathy following chemotherapy with S-1 and cisplatin in a patient with gastric cancer: a case report","volume":"31","author":"Muto","year":"2017","journal-title":"In Vivo"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151341_bib0078","doi-asserted-by":"crossref","first-page":"154","DOI":"10.34067\/KID.0005622020","article-title":"Rondon-Berrios H. Hypomagnesemia in the cancer patient","volume":"2","author":"Workeneh","year":"2021","journal-title":"Kidney360"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151341_bib0079","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1001\/archinte.1984.00350220052010","article-title":"Hypomagnesemia associated with cisplatin combination chemotherapy","volume":"144","author":"Flombaum","year":"1984","journal-title":"Arch Intern Med."},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151341_bib0080","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00280-017-3392-8","article-title":"Electrolyte disorders with platinum-based chemotherapy: mechanisms, manifestations and management","volume":"80","author":"Oronsky","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"10.1016\/j.semnephrol.2023.151341_bib0081","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1007\/s10157-009-0215-1","article-title":"Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats","volume":"13","author":"Yokoo","year":"2009","journal-title":"Clin Exp Nephrol."},{"issue":"7","key":"10.1016\/j.semnephrol.2023.151341_bib0082","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0101902","article-title":"Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection","volume":"9","author":"Kidera","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.semnephrol.2023.151341_bib0083","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1681\/ASN.2007070792","article-title":"Mechanism of hypokalemia in magnesium deficiency","volume":"18","author":"Huang","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151341_bib0084","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2265.1976.tb01947.x","article-title":"Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency","volume":"5","author":"Rude","year":"1976","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151341_bib0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/23772484.2016.1198231","article-title":"Differential diagnosis of hyponatremia induced by cisplatin-containing chemotherapy: syndrome of inappropriate secretion of antidiuretic hormone (SIADH) or renal salt wasting syndrome (RSWS)","volume":"1","author":"Inamori","year":"2016","journal-title":"Acta Oto-Laryngologica Case Reports"},{"issue":"12","key":"10.1016\/j.semnephrol.2023.151341_bib0086","first-page":"606","article-title":"Cisplatin-induced acute kidney injury and renal salt wasting syndrome","volume":"38","author":"Russo","year":"2021","journal-title":"Fed Pract"},{"issue":"8","key":"10.1016\/j.semnephrol.2023.151341_bib0087","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1097\/SMJ.0b013e3181e63682","article-title":"Cisplatin-induced renal salt wasting syndrome","volume":"103","author":"Hamdi","year":"2010","journal-title":"South Med J"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151341_bib0088","doi-asserted-by":"crossref","first-page":"e29592","DOI":"10.1002\/pbc.29592","article-title":"Carboplatin-induced renal salt-wasting syndrome in pediatric patients with intracranial germ cell tumors and concomitant diabetes insipidus","volume":"69","author":"Wan","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151341_bib0089","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/asheducation-2008.1.159","article-title":"The anemia of inflammation\/malignancy: mechanisms and management","volume":"2008","author":"Adamson","year":"2008","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.semnephrol.2023.151341_bib0090","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1172\/JCI117840","article-title":"Cisplatin-associated anemia: an erythropoietin deficiency syndrome","volume":"95","author":"Wood","year":"1995","journal-title":"J Clin Invest"},{"issue":"19","key":"10.1016\/j.semnephrol.2023.151341_bib0091","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/jnci\/91.19.1616","article-title":"Chemotherapy-induced anemia in adults: incidence and treatment","volume":"91","author":"Groopman","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151341_bib0092","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1200\/JCO.1994.12.5.1058","article-title":"Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo","volume":"12","author":"Cascinu","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151341_bib0093","doi-asserted-by":"crossref","first-page":"37","DOI":"10.34067\/KID.0004802021","article-title":"Urine neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 to detect pediatric cisplatin-associated acute kidney injury","volume":"3","author":"McMahon","year":"2021","journal-title":"Kidney360"},{"issue":"1","key":"10.1016\/j.semnephrol.2023.151341_bib0094","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12882-022-02760-4","article-title":"Urinary L-type fatty acid-binding protein is a predictor of cisplatin-induced acute kidney injury","volume":"23","author":"Yanishi","year":"2022","journal-title":"BMC Nephrol"},{"issue":"5","key":"10.1016\/j.semnephrol.2023.151341_bib0095","doi-asserted-by":"crossref","first-page":"439","DOI":"10.34172\/bi.2022.22132","article-title":"Reduced inflammation following human endometrial stromal\/stem cell injection into male Wistar rats with cisplatin-induced acute kidney injury","volume":"12","author":"Zeinali","year":"2022","journal-title":"Bioimpacts"},{"key":"10.1016\/j.semnephrol.2023.151341_bib0096","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.935937","article-title":"Oroxylin A ameliorates AKI-to-CKD transition through maintaining PPAR\u03b1-BNIP3 signaling-mediated mitochondrial homeostasis","volume":"13","author":"Yao","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.semnephrol.2023.151341_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154306","article-title":"Role of curcumin in the treatment of acute kidney injury: research challenges and opportunities","volume":"104","author":"Cai","year":"2022","journal-title":"Phytomedicine"},{"issue":"3","key":"10.1016\/j.semnephrol.2023.151341_bib0098","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.xkme.2020.01.010","article-title":"SGLT2 inhibitors for treatment of refractory hypomagnesemia: a case report of 3 patients","volume":"2","author":"Ray","year":"2020","journal-title":"Kidney Med"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929523000517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T23:42:10Z","timestamp":1759448530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929523000517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S0270929523000517"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151341","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cisplatin Nephrotoxicity: Novel Insights Into Mechanisms and Preventative Strategies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2023.151341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151341"}}